Drug intelligence / Profile preview

NTQ2494

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

NTQ2494 is an orally bioavailable, selective small molecule inhibitor of the receptor tyrosine kinase AXL. It is being developed as an anti-tumor molecular targeted therapy with potential antineoplastic activity. By binding to and inhibiting AXL activation, NTQ2494 may block downstream signaling pathways involved in tumor cell survival, proliferation, and metastasis. The drug is currently in Phase 1 clinical trials for advanced hematological malignancies and was initially developed by Nanjing Chia Tai Tianqing Pharmaceutical.

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on NTQ2494.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTQ2494.

Explore the full profile